Pharmacometrics researcher

Zack (Zehua) Wang

Model-informed evidence for better dosing, clinical trials, and treatment decisions.

Get up and go or sit around and die.

--"MAURI TU - MAURI ORA, MAURI NOHO - MAURI MATE."

Pharmacometrics Clinical trial simulation Model-informed dosing Disease progression modelling

I am Zack (Zehua) Wang, a PhD candidate in Pharmacology at the University of Auckland. I use pharmacometric models and simulation to study dosing, treatment effects and disease progression.

My doctoral research develops a clinical trial simulation framework to evaluate vancomycin dosing and sampling strategies. I also investigate antibody treatment in Alzheimer’s disease, including variation in response and whether benefit persists after treatment stops.

My earlier work includes PBPK/PD modelling, experimental studies of drug disposition and pharmacometric analyses in early-phase clinical trials. I work with NONMEM, R, Phoenix WinNonlin and Python.

I welcome collaborations and opportunities in pharmacometrics, clinical pharmacology and model-informed drug development.

Selected research

View all projects
01 Vancomycin AUC-guided dosing Bayesian dose prediction, target concentration intervention, and clinical trial simulation. 02 Alzheimer's disease progression Longitudinal modelling of treatment effects, disease trajectories, and uncertainty.

Reading

Alex Kesin · Arena ·

Borrowing Strength

“The way to advance your field is to look over the fence into somebody else’s field and see if you can borrow something.”

— Carl Peck, quoted by Alex Kesin

Alex Kesin traces the origins of population pharmacokinetics and NONMEM through the work of Barr Rosenberg, Lewis Sheiner, Stuart Beal and Alison Boeckmann. The article explores how information from a population can inform individual predictions when measurements are sparse, offering historical context for pharmacometric modelling and dose individualisation.

Shared by Nick